Article

EDUCATED PATIENT CLL Webinar

Author(s):

Join us online for an informative chronic lymphocytic leukemia webinar on Wednesday, June 17, 2020, at 7 - 8 p.m. ET.

Join us online for an informative Chronic Lymphocytic Leukemia webinar including topics highly relevant to patients, caregivers and advocates right now. Participants will have the opportunity to submit questions to be answered live by our expert panel. On this webinar you’ll also hear from the experts on topics such as:

  • Current trends with CLL diagnoses
  • The use of telemedicine
  • Treatment options
  • Mental health and wellness

Register now for access to CURE®’s community of leukemia and lymphoma experts.

https://bit.ly/June17-CLLWebinar

PRESENTING FACULTY

Andre H. Goy, MD

Physician in Chief Hackensack Meridian Health Oncology Care Transformation Service

Chairman & Chief Physician Officer - John Theurer Cancer Center

Lydia Pfund Chair for Lymphoma

Academic Chairman Oncology- Hackensack Meridian School of Medicine at Seton Hall University

Professor of Medicine — Georgetown University

Susan M. O'Brien MD

Professor, Associate Director for Clinical Science

Chao Family Comprehensive Cancer Center at University of California, Irvine

Lori Leslie, MD

Lead for the Indolent lymphoma program in the Lymphoma Division

John Theurer Cancer Center

Andrew Ip, MD

Hematology Attending

John Theurer Cancer Center

Register today! https://bit.ly/June17-CLLWebinar

Newsletter

Stay up to date on cancer updates, research and education

Related Videos
Image of doctor.
Image of man with black hair.
Picture of Dr. Pouneh Razavi
Richard Winneker gathers input from patients and researchers to shape MPN research, aiming to fund strategic projects for this population.
Dr. Curtiland Deville Jr. discusses the importance of crafting an individualized treatment plan for patients with prostate cancer.
Image of man.
Image of Crispino
Image of Dr. Reznick
Picture of Joy Anderson
Some patients with relapsed/refractory diffuse large B-cell lymphoma whose disease progressed after CAR-T cell therapy, responded to odronextamab.
Related Content